


Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

Amendments to the Claims:

Please cancel Claim 10, 19, 26 and 28 without prejudice or disclaimer, amend Claims 1, 11, 23-25 and 27, and add new Claims 29-31 as set forth below.

1. (Currently amended) A compound of the formula (I):



wherein:

V is selected from CH₂ and NH, and W is selected from NR¹ and NR²; or V is selected from NR¹ and NR², and W is selected from CH₂ and NH;


X is selected from CH₂ and CHOH in the R or S-configuration;

Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH[[,]] and NR¹ and NR² then Y is hydrogen;


Z is selected from hydrogen, halogen, hydroxy, SQ, OQ and Q, where Q is an optionally substituted alkyl, aralkyl or aryl group;

R¹ is a radical of the formula (II)

Applicants: Gary Brian Evans, et al.
 Appl. No.: 10/524,995
 Filing Date: September 27, 2005



~~R³ is a radical of the formula (III)~~



A is selected from N, CH and CR, where R is selected from halogen, optionally substituted alkyl, aralkyl or aryl, OH, NH₂, NHR³, NR³R⁴ and SR⁵, where R³, R⁴ and R⁵ are each optionally substituted alkyl, aralkyl or aryl groups;

B is selected from OH, NH₂, NHR⁶, SH, hydrogen and halogen, where R⁶ is an optionally substituted alkyl, aralkyl or aryl group;

D is selected from OH, NH₂, NHR⁷, hydrogen, halogen and SCH₃, where R⁷ is an optionally substituted alkyl, aralkyl or aryl group;

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

E is selected from N and CH;

G is selected from CH₂ and NH, or G is absent, provided that where W is NR¹ ~~or NR²~~ and G is NH then V is CH₂, and provided that where V is NR¹ ~~or NR²~~ and G is NH then W is CH₂,

or a tautomer thereof, or a pharmaceutically acceptable salt thereof, ~~or an ester thereof,~~
~~or a prodrug thereof.~~

2. (Previously presented) A compound as claimed in claim 1, where Z is selected from hydrogen, halogen, hydroxy, SQ and OQ.
3. (Previously presented) A compound as claimed in claim 1, where V is CH₂.
4. (Previously presented) A compound as claimed in claim 1, where X is CH₂.
5. (Previously presented) A compound as claimed in claim 1, where G is CH₂.
6. (Previously presented) A compound as claimed in claim 1, where Z is OH.
7. (Previously presented) A compound as claimed in claim 1, where Z is SQ.
8. (Previously presented) A compound as claimed in claim 1, where Z is Q.
9. (Previously presented) A compound as claimed in claim 1, where W is NR¹.

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

10. (Canceled)
11. (Currently amended) A compound as claimed in claim 1, where W is selected from NH and NH, NR^1 ~~or~~ NR^2 and X is CH_2 .
12. (Previously presented) A compound as claimed in claim 1, where V, X and G are all CH_2 , Z is OH and W is NR^1 .
13. (Previously presented) A compound as claimed in claim 1, where V, X and G are all CH_2 , Z is SQ and W is NR^1 .
14. (Previously presented) A compound as claimed in claim 1, where Y is hydrogen.
15. (Previously presented) A compound as claimed in claim 1, where Y is hydroxy.
16. (Previously presented) A compound as claimed in claim 1, where B is hydroxy.
17. (Previously presented) A compound as claimed in claim 1, where B is NH_2 .
18. (Previously presented) A compound as claimed in claim 1, where A is CH.
19. (Canceled)

Applicants: Gary Brian Evans, et al.

Appl. No.: 10/524,995

Filing Date: September 27, 2005

20. (Previously presented) A compound as claimed in claim 1, where D is H.

21. (Previously presented) A compound as claimed in claim 1, where D is NH₂.

22. (Previously presented) A compound as claimed in claim 1, where E is N.

23. (Currently amended) A compound as claimed in claim 1, which is:

(3R,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

(3R,4R)-1-[(9-Deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

~~(3R,4R)-1-[(8-aza-9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)~~
pyrrolidine;

~~(3R,4R)-1-[(8-aza-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;~~

(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(2-phenylethyl)pyrrolidine;

(3S,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3,4-dihydroxy-4-methylthiomethyl
pyrrolidine;

(3R,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)
pyrrolidine;

N-(9-Deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol;

N-(9-deazahypoxanthin-9-yl)methyl-1,4-dideoxy-1,4-imino-D-ribitol;

~~(3R,4R)-3-hydroxy-4-hydroxymethyl-1-(hypoxanthin-9-yl)pyrrolidine;~~

(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine;

(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)pyrrolidine;

~~(3R,4S)-1-[(8-aza-9-deezaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)~~
pyrrolidine;

(3R,4R)-1-[(9-deazaguanin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

Applicants: Gary Brian Evans, et al.

Appl. No.: 10/524,995

Filing Date: September 27, 2005

(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(4-chlorophenylthiomethyl)
pyrrolidine;

(3R,4R)-1-[(6-chloro-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)
pyrrolidine;

(3R,4R)-1-[(6-azido-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)
pyrrolidine; or

(3R,4R)-1-[(9-deazaadenin-9-yl)methyl]-3-acetoxy-4-(acetoxymethyl)pyrrolidine;
or a pharmaceutically acceptable salt thereof, ~~or an ester thereof, or a prodrug thereof.~~

24. (Currently amended) A pharmaceutical composition comprising a
pharmaceutically effective amount of a compound as claimed in claim 1 and a carrier.

25. (Currently amended) A method of treating a subject having a disease or
condition in which it is desirable to inhibit purine phosphoribosyltransferase, purine
nucleoside phosphorylase, 5'-methylthio adenosine phosphorylase, 5'-
methylthioadenosine nucleosidase and/or nucleoside hydrolase comprising
administering a ~~pharmaceutically effective amount of a~~ compound as claimed in claim 1
to the subject in an amount effective to inhibit purine phosphoribosyltransferase, purine
nucleoside phosphorylase, 5'-methylthio adenosine phosphorylase, 5'-
methylthioadenosine nucleosidase and/or nucleoside hydrolase, a patient requiring
~~treatment. wherein the disease or condition is a cancer, a bacterial infection, a protozoal~~
infection, a T-cell mediated disease or a transplant rejection.


26. (Canceled)

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

27. (Currently amended) The method of claim 25, ~~26~~, where the T-cell mediated disease is psoriasis or [[,]] arthritis ~~or transplant rejection~~.

28. (Canceled)

29. (New) The compound of claim 1 having the structure:



or a pharmaceutically acceptable salt thereof.

30. (New) The compound of claim 1, wherein the salt is derived from an acid selected from the group consisting of hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, lactic acid, fumaric acid, succinic acid, tartaric acid, gluconic acid, citric acid, methanesulfonic acid and p-toluenesulfonic acid.

31. (New) The compound of claim 29, wherein the salt is a hydrochloride salt.